Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
Friday, September 20, 2024Evaxion Biotech AS a clinicalstage TechBio company specializing in developing AIImmunology powered vaccines launches an enhanced version of its clinically validated AIImmunology platform with an update of its EDEN
U.S. grants Vidac Pharma patent offering broad protection of mode of action underlying its oncology drug candidates
Friday, September 20, 2024Vidac Pharma Holdings Plc a clinicalstage oncology biopharmaceutical company pioneering a novel class of cancer treatments today announces that the United States Patent and Trademark Office USPTO has issued a patent to the company offering broad prot...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
Thursday, September 19, 2024OXB a quality and innovationled cell and gene therapy CDMO today announces the launch of its new corporate brand Oxford Biomedica is rebranding as OXB unveiling a more modern and recognisable visual identity that reinforces its transformation
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
Thursday, September 19, 2024Revive Therapeutics Ltd a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures announced today its strategic focus on dedicating its resources to advancing
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
Wednesday, September 18, 2024Sonnet BioTherapeutics Holdings Inc a clinicalstage company developing targeted immunotherapeutic drugs today announced the completion of enrollment and initiation of dosing in its Phase SB clinical trial of SON ILFHAB in adult patients
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment
Wednesday, September 18, 2024IGC Pharma Inc announced data that reinforces the therapeutic potential of IGCAD as a diseasemodifying treatment for Alzheimers disease The data highlights IGCADs promising effects on tau tangles and spatial memory
SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024
Monday, September 16, 2024SOPHiA GENETICS a cloudnative healthcare technology company and a leader in datadriven medicine will unveil new research at the European Society for Medical Oncology ESMO The study conducted in collaboration with AstraZeneca
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors
Friday, September 13, 2024ITM Isotope Technologies Munich SE ITM a leading radiopharmaceutical biotech company and Debiopharm wwwdebiopharmcom a Swissbased global biopharmaceutical company aiming to establish tomorrow
Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme
Friday, September 13, 2024Epitopea a transatlantic cancer immunotherapeutics company developing accessible offtheshelf RNAbased immunotherapies announces it has been awarded a grant
Bioversys Announces Strategic Investment From GIBF2 and Launch of BV100 Clinical Program in China
Thursday, September 12, 2024BioVersys AG a multiasset clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious lifethreatening infections caused by multidrug resistant MDR bacteria
